Share on LinkedInShare on LinkedIn

ARTICLE · 16 MAY 2025

Court Finds Eculizumab Patent Neither Anticipated Nor Obvious

In the first PMNOC decision of the year, Justice Furlanetto upheld the validity of claims 1 and 2 of Alexion's patent no. 2,645,810 which is directed to the antibody...

CanadaIntellectual Property

In the first PMNOC decision of the year, Justice Furlanetto upheld the validity of claims 1 and 2 of Alexion's patent no. 2,645,810 which is directed to the antibody, eculizumab (SOLIRIS).

Claims 1 and 2 recite the following:

  1. An antibody that binds C5 comprising a heavy chain consisting of SEQ ID NO:2 and a light chain consisting of SEQ ID NO:4.
  2. A pharmaceutical composition comprising the antibody of claim 1 and a carrier.

Amgen asserted that claims 1 and 2 were anticipated by example 4 of United States Patent Application No. 2003/023972 and were obvious in view of the state of the art. Justice Furlanetto held that the claims were not invalid for either anticipation or obviousness.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from